Dr Reddys Laboratories Ltd (500124)
Copy of Investor Presentation
AI summary
- Reported Q1FY27 revenues ₹8,071 Cr +6% YoY, EBITDA ₹1,009 Cr +56% YoY, margin 12.5%
- EBITDA margin 15.4% excluding semaglutide API impact; net cash surplus ₹3,058 Cr
- Launched generic semaglutide injection in Canada, bosutinib 400mg in US with 180-day exclusivity
- North America revenues ₹2,205 Cr +35% YoY; India revenues ₹1,718 Cr +17% YoY; Emerging Markets ₹1,833 Cr +31% YoY
- Received USFDA Form 483 with 7 observations at biologics facility; semaglutide batches out of specification
- Partnered with Innoviva for XACDURO antibiotic in emerging markets; Fast Track for ALS drug COYA 302
- ESG: 25 years on NYSE, top 1% FTSE Russell, ranked 165th globally in sustainability
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 500124 — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add 500124 to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Dr Reddys Laboratories Ltd
Important.
The summary above is generated automatically from Dr Reddys Laboratories Ltd's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.